Pharmacokinetic modeling and dosimetric planning of radionuclide therapy of bone metastases

A. V. Matveev
{"title":"Pharmacokinetic modeling and dosimetric planning of radionuclide therapy of bone metastases","authors":"A. V. Matveev","doi":"10.21870/0131-3878-2022-31-1-49-63","DOIUrl":null,"url":null,"abstract":"This paper discusses the features of modeling and calculating the pharmacokinetic and dosimetric characteristics of osteotropic radiopharmaceuticals based on a compartment model of their transport in the human body with bone metastases. A software package for pharmacokinetic modeling and dosimetric planning of palliative radionuclide therapy of bone metastases using clinical radiometric data has been developed and tested. Within the framework of the four-compartment model, a method for determining absorbed doses in critical organs and tissues through their masses and through S-factors is proposed. Three approaches to the appointment of the activity of a radiopharmaceutical and the features of individual dosimetric planning of radio-nuclide therapy of bone metastases are considered and analyzed. For 10 patients with bone metastases, individual kinetic parameters of transport (transport constants of the model) of the radi-opharmaceutical \"Sm-153-oxabifor\" were identified during its intravenous intake into the body and calculations of absorbed doses in bone tissues and metastases, the circulatory system, kidneys and bladder were performed, taking into account its periodic emptying. It is shown that when the standard and specific activities of Sm-153-oxabifor are introduced into the patient's body (the first and second approaches), the absorbed doses in 10 patients differ by 5-6 times, while cases of under- or over-irradiation of bone tissues with metastases are detected, which can significantly reduce the effectiveness of radionuclide therapy or adversely affect the patient's condition later. The individual injectable activity of Sm-153-oxabifor calculated within the framework of the third approach for 10 patients varies widely from 19 to 165 mCi, while there are no cases of under- or over-irradiation of bone tissues. The dose loads on the circulatory system, kidneys and bladder for all patients are tolerant and do not exceed the maximum permissible values.","PeriodicalId":6315,"journal":{"name":"\"Radiation and Risk\" Bulletin of the National Radiation and Epidemiological Registry","volume":"76 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"\"Radiation and Risk\" Bulletin of the National Radiation and Epidemiological Registry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21870/0131-3878-2022-31-1-49-63","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

This paper discusses the features of modeling and calculating the pharmacokinetic and dosimetric characteristics of osteotropic radiopharmaceuticals based on a compartment model of their transport in the human body with bone metastases. A software package for pharmacokinetic modeling and dosimetric planning of palliative radionuclide therapy of bone metastases using clinical radiometric data has been developed and tested. Within the framework of the four-compartment model, a method for determining absorbed doses in critical organs and tissues through their masses and through S-factors is proposed. Three approaches to the appointment of the activity of a radiopharmaceutical and the features of individual dosimetric planning of radio-nuclide therapy of bone metastases are considered and analyzed. For 10 patients with bone metastases, individual kinetic parameters of transport (transport constants of the model) of the radi-opharmaceutical "Sm-153-oxabifor" were identified during its intravenous intake into the body and calculations of absorbed doses in bone tissues and metastases, the circulatory system, kidneys and bladder were performed, taking into account its periodic emptying. It is shown that when the standard and specific activities of Sm-153-oxabifor are introduced into the patient's body (the first and second approaches), the absorbed doses in 10 patients differ by 5-6 times, while cases of under- or over-irradiation of bone tissues with metastases are detected, which can significantly reduce the effectiveness of radionuclide therapy or adversely affect the patient's condition later. The individual injectable activity of Sm-153-oxabifor calculated within the framework of the third approach for 10 patients varies widely from 19 to 165 mCi, while there are no cases of under- or over-irradiation of bone tissues. The dose loads on the circulatory system, kidneys and bladder for all patients are tolerant and do not exceed the maximum permissible values.
放射性核素治疗骨转移瘤的药代动力学模型和剂量学规划
本文讨论了基于骨转移性药物在人体内运输的室室模型,对其药代动力学和剂量学特性进行建模和计算的特点。已经开发并测试了一个软件包,用于使用临床放射学数据对骨转移的姑息性放射性核素治疗进行药代动力学建模和剂量规划。在四室模型的框架内,提出了一种通过质量和s因子确定关键器官和组织吸收剂量的方法。本文考虑并分析了放射性药物活性测定的三种方法以及放射性核素治疗骨转移的个体剂量计划的特点。对10例骨转移患者,确定了放射性药物“Sm-153-oxabifor”在静脉进入体内时的转运动力学参数(模型的转运常数),并考虑其周期性排空,计算了骨组织和转移、循环系统、肾脏和膀胱的吸收剂量。研究表明,将Sm-153-oxabifor的标准活性和特异活性引入患者体内(第一种和第二种方法),10例患者的吸收剂量相差5-6倍,同时检测到转移骨组织的照射不足或过度,这可能会显著降低放射性核素治疗的有效性或对患者后来的病情产生不利影响。在第三种方法的框架内计算的10例患者的Sm-153-oxabifor的个体注射活性在19至165 mCi之间变化很大,同时没有骨组织照射不足或过度的病例。所有患者的循环系统、肾脏和膀胱的剂量负荷都是耐受的,不超过最大允许值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信